866-997-4948(US-Canada Toll Free)

Fasiglifam (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jul 2013

Category :

Metabolic Disorders

No. of Pages : 61 Pages


GlobalData has released its new report, Fasiglifam (Type 2 Diabetes) Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Fasiglifam (TAK-875) is a first-in-class GPR40/FFAR1 receptor agonist, currently being investigated in Phase III clinical trials by Takeda Pharmaceutical Company.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Fasiglifam including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Fasiglifam for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China. 

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Fasiglifam performance
  • Obtain sales forecast for Fasiglifam from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10

3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16

4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19

5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26

6 Opportunity and Unmet Need 28
6.1 Overview 28
6.2 Unmet Needs 29
6.2.1 Drugs Providing Sustained Glycemic Control 29
6.2.2 Drugs with Non-Glycemic Benefits 30
6.2.3 Increased Patient Compliance 31
6.2.4 Drugs with Improved Side-Effect Profiles 32
6.2.5 Earlier Diagnosis 33
6.3 Unmet Needs Gap Analysis 34
6.4 Oral Therapy with Sustainable Efficacy 35
6.5 Oral Therapy Offering Weight Loss 35
6.6 Cardio-metabolic Therapy 36
6.7 Promotion of Type 2 Diabetes Drugs in Emerging Markets 36

7 Pipeline Assessment 37
7.1 Overview 37
7.2 Promising Drugs in Clinical Development 38

8 Fasiglifam (TAK-875) 43
8.1 Overview 43
8.2 Efficacy 44
8.3 Safety 45
8.4 Dosing and Formulation 46
8.5 Potential Clinical Positioning 46
8.6 Potential Commercial Positioning 46
8.7 Pricing and Reimbursement 47
8.8 SWOT Analysis 47
8.9 Forecast 48

9 Appendix 49
9.1 Bibliography 49
9.2 Abbreviations 51
9.3 Methodology 53
9.4 Forecasting Methodology 53
9.4.1 Diagnosed Type 2 Patients 53
9.4.2 Percent Drug-Treated Patients 54
9.4.3 Drugs Included in Each Therapeutic Class 54
9.4.4 General Pricing Assumptions 55
9.4.5 Pricing of Pipeline Agents 55
9.5 Physicians and Specialists Included in this Study 56
9.6 About the Authors 58
9.6.1 Analyst II - CVMD 58
9.6.2 Therapy Director - CVMD and Infectious Disease 58
9.6.3 Global Head of Healthcare 59
9.7 About GlobalData 60
9.8 Disclaimer 60

List of Table


Table 1: Symptoms of Type 2 Diabetes 17
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 18
Table 3: Treatment Guidelines for Type 2 Diabetes 20
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 23
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 27
Table 6: Overall Unmet Needs - Current Level of Attainment 28
Table 7: Clinical Unmet Needs - Gap Analysis, 2013 34
Table 8: Type 2 Diabetes - Phase Pipeline, 2012 40
Table 9: Comparison of Therapeutic Classes in Development for Type 2 Diabetes, 2012 41
Table 10: Product Profile - Fasiglifam 44
Table 11: Fasiglifam SWOT Analysis, 2013 47
Table 12: Global Sales Forecasts ($m) for Fasiglifam, 2012--2022 48
Table 13: Number of High-Prescribing Physicians Surveyed 57

List of Chart


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy 22
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Type 2 Diabetes, 2012-2022 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *